Conference Coverage

Sequencing Vemurafenib, Cobimetinib, and Atezolizumab for Patients With High-Risk Melanoma

07/19/2024

Paolo Ascierto, MD, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy, discusses primary results from the phase 2 NEO-TIM trial which sought to determine the optimal sequencing of vemurafenib, cobimetinib, and atezolizumab among patients with patients with high-risk melanoma.

Source:

Ascierto P. Combination or sequence of vemurafenib, cobimetinib, and atezolizumab in high-risk, resectable melanoma (NEO-TIM): Primary results. Presented at the ASCO Annual Meeting. May 31 – June 4, 2024; Chicago, IL. Abstract #LBA9513

© 2024 HMP Global. All Rights Reserved.

Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.

Recent News

News

Pembrolizumab Plus Gemcitabine-Platinum Doublet Chemotherapy Improves Survival Regardless of Platinum Agent for Urothelial Carcinoma

11/19/2024

Stephanie Holland ;

Subset analysis results from the phase 3 KEYNOTE-361 study demonstrated that the addition of pembrolizumab to gemcitabine-platinum doublet chemotherapy improved survival for patients with advanced or metastatic urothelial carcinoma,...

Subset analysis results from the...

11/19/2024

Oncology

News

Addition of Toripalimab to First-Line Chemotherapy Improves Survival for Patients With Extensive-Stage Small Cell Lung Cancer

11/19/2024

Stephanie Holland ;

Results from the phase 3 EXTENTORCH trial demonstrated that the addition of toripalimab to first-line chemotherapy significantly improved survival among patients with extensive-stage small cell lung cancer.

Results from the phase 3...

11/19/2024

Oncology

News

Adjuvant Chemotherapy Followed by Radiation May Benefit Patients With High-Risk Endometrial Cancer

11/19/2024

Allison Casey ;

According to a phase 2 trial, adjuvant docetaxel-cisplatin followed by radiation therapy may benefit patients with high-risk endometrial cancer.

According to a phase 2 trial,...

11/19/2024

Oncology

News

Robotic Laparoscopy May Have Easier Recovery For Patients With Early-Stage, Low Risk Endometrial Cancer

11/19/2024

Allison Casey ;

According to a randomized clinical trial, there may be benefits to inflammation processes, tissue damage, stress and recovery time with robotic laparoscopy for early-stage endometrial cancer compared to conventional laparoscopy.

According to a randomized...

11/19/2024

Oncology

News

UGN-102 Chemoablation as TURBT Alternative for Patients With Recurrent Low-Grade Non-Muscle Invasive Bladder Cancer

11/19/2024

Stephanie Holland ;

According to results from the phase 3 ENVISION trial, chemoablation with UGN-102 demonstrates clinical promise as an alternative to standard-of-care transurethral resection of the bladder tumor for patients with recurrent low-grade...

According to results from the...

11/19/2024

Oncology

News

Tumor Mutational Status May Predict Recurrence, Survival Patterns for Patients With Early-Stage Non-Small Cell Lung Cancer

11/18/2024

Stephanie Holland ;

According to results from a retrospective analysis, tumor mutational status can potentially predict recurrence and survival patterns for patients with surgically resected, stage I non-small cell lung cancer.

According to results from a...

11/18/2024

Oncology

News

FDA Grants Approval to Revumenib for Patients With R/R Acute Leukemia With KMT2A Translocation

11/17/2024

On November 15, 2024, the FDA approved menin inhibitor revumenib for adult and pediatric patients 1 year and older with relapsed/refractory acute leukemia with KMT2A translocation.

On November 15, 2024, the FDA...

11/17/2024

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology